As the lowest sodium (80mg sodium for 9g dose), once-nightly treatment currently in development, TRN-257 has the potential to be the new standard of care for adults with narcolepsy (cataplexy or ...

A judge said he will approve a $7 billion settlement between the maker of OxyContin and people with addiction, states, counties and Native American tribes. There have been thousands of lawsuits filed.

As technology reshapes the pharmaceutical landscape, medical affairs teams must adapt to remain relevant, Jeff Keller, president of medical affairs at Propel Health, told Fierce. Keller emphasized the ...

Two new studies point in opposite directions. A large new study conducted in Spain and Italy found that beta blockers, drugs often used to slow the heart rate and lower blood pressure, did not provide ...

New research explains how low levels of the electrolyte sodium in the blood can disrupt the timing of the heartbeat in patients taking widely used rhythm-control medications such as flecainide, which ...

Steven Poelzing (left) and Gregory Hoeker, researchers at the Fralin Biomedical Research Institute at VTC, collaborated on a new study published in the journal Heart Rhythm revealing why low blood ...

In the notoriously expensive business of drug development, SiteOne Therapeutics made do with little. The biotechnology startup formed in 2010, aiming to create new, non-addictive pain relievers at a ...

Nanjing Deheng Pharmaceutical Technology Co. Ltd. and Nanjing Delova Biotech Co. Ltd. have discovered new sodium channel protein type 10 subunit α (SCN10A; Nav1.8) blockers reported to be useful for ...

Last week, the Food and Drug Administration approved Journavx, the first non-addictive opioid-like pain medication. Scientific discoveries at Yale were key to the development of the drug. Journavx, ...

The use of Journavx for moderate to severe pain has not been studied beyond 14 days. The Food and Drug Administration (FDA) has approved Journavx™ (suzetrigine) for the treatment of moderate to severe ...

Note: On January 30, 2025 the FDA approved the first-in-class non-opioid analgesic Journavx (suzetrigine) for the treatment of moderate to severe acute pain in adults. The novel drug reduces pain by ...